Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature

Clinical Lymphoma

Volumn 5, Issue 3, 2004, Pages 202-204

  Ansell, Stephen M ^a   Schilder, Russell J ^b   Pieslor, Peter C ^c   Gordon, Leo I ^d   Emmanouilides, Christos ^e   Vo, Katie ^c   Czuczman, Myron S ^f   Witzig, Thomas E ^a   Theuer, Charles ^c   Molina, Arturo ^c  

^a MAYO CLINIC   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c BIOGEN   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Radioimmunotherapy; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; INTERFERON; MESNA; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; HEMATOLOGIC DISEASE; HUMAN; NEUTROPENIA; NONHODGKIN LYMPHOMA; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTOPENIA;

EID: 13644267438     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2004.n.028     Document Type: Article

References (8)

1. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3262-3269.
2. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-tabeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-2463.
3. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336-4342.
4. Gordon L, Witzig T, Schilder R, et al. High-dose therapy can be safely and successfully administered after Zevalin. Proc Am Soc Clin Oncol 2001; 20:232b (Abstract #2681).
5. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:1263-1270.
6. Schilder RJ, Witzig TE, Gordon L, et al. 90Y ibritumomab tiuxetan (Zevalin®) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma. Proc Am Soc Clin Oncol 2002; 21:267a (Abstract #1064).
7. Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3885-3890.
8. Saleh F, Saleh M, Witzig T, et al. Rituximab administration subsequent to ibritumomab tiuxetan (Zevalin) radioimmunotherapy. Proc Am Soc Clin Oncol 2002; 21:8a (Abstract #30).